Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Importance of PK/PD Data-Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics

Rakesh Kumar, Benjamin Suttle

Mol Cancer Ther (2011) 10 (11): 2028.

https://doi.org/10.1158/1535-7163.MCT-11-0728

Published: 08 November 2011

View article titled, The Importance of PK/PD Data-Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics

Journal Articles

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz-Munoz, Terence Tang, Rakesh Kumar, Robert S. Kerbel

Mol Cancer Ther (2010) 9 (4): 996–1006.

https://doi.org/10.1158/1535-7163.MCT-09-0960

Published: 07 April 2010

View article titled, Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

Journal Articles

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

William M. Merritt, Alpa M. Nick, Amy R. Carroll, Chunhua Lu, Koji Matsuo, Melissa Dumble, Nicholas Jennings, ShuYun Zhang, Yvonne G. Lin, Whitney A. Spannuth, Aparna A. Kamat, Rebecca L. Stone, Mian M.K. Shahzad, Robert L. Coleman, Rakesh Kumar, Anil K. Sood

Mol Cancer Ther (2010) 9 (4): 985–995.

https://doi.org/10.1158/1535-7163.MCT-09-0967

Published: 07 April 2010

View article titled, Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

Includes: Supplementary data

Journal Articles

Abstract C58: Causal Network™ Modeling identifies common and unique mechanisms for sensitivity to the PI3K inhibitor GSK1059615 and the AKT inhibitor GSK690693

Michael P. Macoritto, Daphna Laifenfeld, Natalie Catlett, Milena Jorge, Andrea Matthews, Kurt R. Auger, Rakesh Kumar

Mol Cancer Ther (2009) 8 (12_Supplement): C58.

https://doi.org/10.1158/1535-7163.TARG-09-C58

Published: 10 December 2009

View article titled, Abstract C58: Causal Network™ Modeling identifies common and unique mechanisms for sensitivity to the PI3K inhibitor GSK1059615 and the AKT inhibitor GSK690693

Journal Articles

Abstract PR-9: Differences in effects on myocardium and mitochondria by VEGF receptor inhibitors suggest separate mechanisms of cardiotoxicity

Kevin French, Catherine Hu, Rakesh Kumar, Jon Renninger, Tracy Gales, Robert Coatney, Kendall Frazier

Mol Cancer Ther (2009) 8 (12_Supplement): PR-9.

https://doi.org/10.1158/1535-7163.TARG-09-PR-9

Published: 10 December 2009

View article titled, Abstract PR-9: Differences in effects on myocardium and mitochondria by VEGF receptor inhibitors suggest separate mechanisms of cardiotoxicity

Journal Articles

Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz‐Munoz, Terence Tang, Anthony Mutsaers, Rakesh Kumar, Robert S. Kerbel

Mol Cancer Ther (2009) 8 (12_Supplement): A9.

https://doi.org/10.1158/1535-7163.TARG-09-A9

Published: 10 December 2009

View article titled, Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

Journal Articles

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Mol Cancer Ther (2009) 8 (10): 2811–2820.

https://doi.org/10.1158/1535-7163.MCT-09-0423

Published: 12 October 2009

View article titled, GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Includes: Supplementary data

Journal Articles

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Rakesh Kumar, Victoria B. Knick, Sharon K. Rudolph, Jennifer H. Johnson, Renae M. Crosby, Ming-Chih Crouthamel, Teresa M. Hopper, Charles G. Miller, Laura E. Harrington, James A. Onori, Robert J. Mullin, Tona M. Gilmer, Anne T. Truesdale, Andrea H. Epperly, Amogh Boloor, Jeffrey A. Stafford, Deirdre K. Luttrell, Mui Cheung

Mol Cancer Ther (2007) 6 (7): 2012–2021.

https://doi.org/10.1158/1535-7163.MCT-07-0193

Published: 09 July 2007

View article titled, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Includes: Supplementary data

Journal Articles

Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor–induced apoptosis

Suresh K. Rayala, Joseph Mascarenhas, Ratna K. Vadlamudi, Rakesh Kumar

Mol Cancer Ther (2006) 5 (2): 230–237.

https://doi.org/10.1158/1535-7163.MCT-05-0276

Published: 27 February 2006

View article titled, Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor–induced apoptosis

Journal Articles

Suppression of Epidermal Growth Factor Receptor, Mitogen-activated Protein Kinase, and Pak1 Pathways and Invasiveness of Human Cutaneous Squamous Cancer Cells by the Tyrosine Kinase Inhibitor ZD1839 (Iressa)

Christopher J. Barnes, Rozita Bagheri-Yarmand, Mahitosh Mandal, Zhibo Yang, Gary L. Clayman, Waun Ki Hong, Rakesh Kumar

Mol Cancer Ther (2003) 2 (4): 345–351.

Published: 01 April 2003

View article titled, Suppression of Epidermal Growth Factor Receptor, Mitogen-activated Protein Kinase, and Pak1 Pathways and Invasiveness of Human Cutaneous Squamous Cancer Cells by the Tyrosine Kinase Inhibitor ZD1839 (Iressa)

NARROW

The Importance of PK/PD Data-Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

Abstract C58: Causal Network™ Modeling identifies common and unique mechanisms for sensitivity to the PI3K inhibitor GSK1059615 and the AKT inhibitor GSK690693

Abstract PR-9: Differences in effects on myocardium and mitochondria by VEGF receptor inhibitors suggest separate mechanisms of cardiotoxicity

Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor–induced apoptosis

Suppression of Epidermal Growth Factor Receptor, Mitogen-activated Protein Kinase, and Pak1 Pathways and Invasiveness of Human Cutaneous Squamous Cancer Cells by the Tyrosine Kinase Inhibitor ZD1839 (Iressa)

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only